Company Number: 14925154

Analysis Date: 2025-07-19 12:06 UTC

1. Risk Rating: LOW to MEDIUM
   The company is newly incorporated (June 2023) and classified as a micro-entity with no overdue filings and positive net current assets. However, limited financial history and modest asset base suggest a cautious rating until operational track record matures.

2. Key Concerns:

• Limited Operating History: With just over one year since incorporation, there is insufficient financial data to assess long-term sustainability or profitability.
• Modest Capitalization: Net assets of £9,130 and fixed assets of £3,764 indicate a small capital base relative to potential operational needs in pharmaceutical manufacture and sales.
• Concentration of Control and Management: One individual holds 75-100% shares and voting rights, and also acts as a current director, which may present governance risks for investors seeking diversified management.

3. Positive Indicators:

• Positive Working Capital: Net current assets of £11,366 imply the company can currently meet short-term liabilities comfortably.
• No Overdue Filings or Compliance Issues: The company’s accounts and confirmation statement are filed on time, indicating good regulatory compliance so far.
• Industry Approvals and Positioning: Website notes FDA approval (KSA) and registrations in EU and UK, which suggest regulatory acceptance of their treatment products, potentially supporting future revenue.
• Small but Stable Workforce: Average of 2 employees reported, consistent with micro-entity status and controlled cost base.

4. Due Diligence Notes:

• Obtain detailed financial performance data (revenue, profit/loss) beyond balance sheet figures to assess operational viability.
• Review cash flow trends and funding sources, especially given modest net assets and potential growth capital requirements.
• Confirm the nature and enforceability of regulatory approvals cited, including any ongoing compliance obligations or risks.
• Assess the background and qualifications of key management, particularly the sole controlling shareholder/director, for governance and strategic execution capabilities.
• Investigate any related party transactions or agreements given single-person control and potential conflicts of interest.